Bad Company: Concurrent Mutations Define Unique Subsets of NSCLC
February 18th 2021The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.
Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma
February 12th 2021Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.
Cancer Staging and Toxicity Framework Should Be Overhauled for the Modern Era
February 8th 2021Formerly, small cell lung cancer was generally considered more chemotherapy sensitive in the short term but also associated with an overall inferior survival outcome; however, the difference in prognosis compared with metastatic non–small cell lung cancer was measured in months—rarely longer.